Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC5A2 | P31639 | 8/20 | 0.47 |
| ▸ | SLC5A1 | P13866 | 5/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | SLC6A4 | P31645 | 3/20 | 0.39 |
| ▸ | HTR2A | P28223 | 2/20 | 0.39 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.39 |
| ▸ | CCR5 | P51681 | 4/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.37 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.37 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.36 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.36 |
| ▸ | PTPRC | P08575 | 1/20 | 0.35 |
| ▸ | PTPRG | P23470 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1539254 | 0.86 | SLC5A2 (0.47) | SLC5A2SLC5A1ALDH1A1SLC6A4HTR2A | |
| SCHEMBL12782162 | 0.85 | CCR5 (0.47) | SLC6A4HTR2AKCNH2CCR5MAPT | |
| SCHEMBL500031 | 0.84 | SLC6A4 (0.37) | SLC5A2SLC5A1ALDH1A1SLC6A4HTR2A | |
| SCHEMBL1539252 | 0.83 | SLC5A2 (0.49) | SLC5A2SLC5A1POLBSLC6A4HTR2A | |
| SCHEMBL29386304 | 0.82 | SLC5A2 (0.53) | SLC5A2SLC5A1ALDH1A1MAPT | |
| SCHEMBL38150 | 0.82 | SLC5A2 (0.53) | SLC5A2SLC5A1ALDH1A1MAPT | |
| SCHEMBL17842 | 0.82 | MEN1 (0.46) | SLC5A2SLC5A1KDM4EALDH1A1POLB | |
| SCHEMBL1457579 | 0.82 | APP (0.40) | SLC5A2SLC5A1SLC6A4HTR2AKCNH2 | |
| SCHEMBL499287 | 0.82 | SLC5A2 (0.38) | SLC5A2SLC5A1SMN1; SMN2SLC6A4HTR2A | |
| SCHEMBL29816996 | 0.82 | MEN1 (0.46) | SLC5A2SLC5A1KDM4EALDH1A1POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 44 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2230907-B1 | BENZYLPHENYL CYCLOHEXANE DERIVATIVES AND METHODS OF USE | THERACOS INC (US) | 2018-05-09 | — | — | EP | disclosed |
| EP-2230907-B1 | BENZYLPHENYL CYCLOHEXANE DERIVATIVES AND METHODS OF USE | THERACOS INC (US) | 2018-05-09 | — | — | EP | disclosed |
| EP-2714636-B9 | FAMILY OF ARYL, HETEROARYL, O-ARYL AND O-HETEROARYL CARBASUGARS | TFCHEM (FR) | 2017-03-22 | — | — | EP | disclosed |
| US-9434670-B2 | Family of aryl, heteroaryl, O-aryl and O-heteroaryl carbasugars | TFCHEM (FR) | 2016-09-06 | — | — | US | disclosed |
| EP-2714636-B1 | FAMILY OF ARYL, HETEROARYL, O-ARYL AND O-HETEROARYL CARBASUGARS | TFCHEM (FR) | 2015-12-16 | — | — | EP | disclosed |
| US-20140105839-A1 | FAMILY OF ARYL, HETEROARYL, O-ARYL AND O-HETEROARYL CARBASUGARS | TF-CHEM (FR) | 2014-04-17 | — | — | US | disclosed |
| WO-2012160218-A1 | FAMILY OF ARYL, HETEROARYL, O-ARYL AND O-HETEROARYL CARBASUGARS | TFCHEM (FR) | 2012-11-29 | — | — | WO | disclosed |
| CN-101103013-B | 1-thio-D-glucitol derivatives | TAISHO PHARMACEUTICAL CO LTD | 2012-05-23 | — | — | CN | disclosed |
| US-8129434-B2 | Benzylphenyl cyclohexane derivatives and methods of use | THERACOS, INC. (US) | 2012-03-06 | — | — | US | disclosed |
| US-8129434-B2 | Benzylphenyl cyclohexane derivatives and methods of use | THERACOS, INC. (US) | 2012-03-06 | — | — | US | disclosed |
| WO-2008144346-A2 | CRYSTAL STRUCTURES OF SGLT2 INHIBITORS AND PROCESSES FOR THEIR PREPARATION | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-11-27 | — | — | WO | disclosed |
| US-20080287529-A1 | CRYSTAL STRUCTURES OF SGLT2 INHIBITORS AND PROCESSES FOR PREPARING SAME | BRISTOL-MYERS SQUIBB COMPANY | 2008-11-20 | — | — | US | disclosed |
| US-20080287529-A1 | CRYSTAL STRUCTURES OF SGLT2 INHIBITORS AND PROCESSES FOR PREPARING SAME | BRISTOL-MYERS SQUIBB COMPANY | 2008-11-20 | — | — | US | disclosed |
| US-20080287529-A1 | CRYSTAL STRUCTURES OF SGLT2 INHIBITORS AND PROCESSES FOR PREPARING SAME | BRISTOL-MYERS SQUIBB COMPANY | 2008-11-20 | — | — | US | disclosed |
| US-20080132563-A1 | 1-Thio-D-Glucitol Derivatives | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2008-06-05 | — | — | US | disclosed |
| CN-101103013-A | 1-thio-D-glucitol derivatives | TAISHO PHARMACEUTICAL CO LTD (JP) | 2008-01-09 | — | — | CN | disclosed |
| EP-1845095-A1 | 1-THIO-D-GLUCITOL DERIVATIVES | TAISHO PHARMACEUTICAL CO., LTD (JP) | 2007-10-17 | — | — | EP | disclosed |
| EP-1791852-A2 | C-ARYL GLUCOSIDE SGLT2 INHIBITORS AND METHOD FOR THEIR PRODUCTION | Brystol-Myers Squibb Company (US) | 2007-06-06 | — | — | EP | disclosed |
| WO-2006034489-A2 | C-ARYL GLUCOSIDE SGLT2 INHIBITORS AND METHOD FOR THEIR PRODUCTION | BRISTOL-MYERS SQUIBB COMPANY (US) | 2006-03-30 | — | — | WO | disclosed |
| US-20060063722-A1 | C-aryl glucoside SGLT2 inhibitors and method | BRISTOL-MYERS SQUIBB COMPANY | 2006-03-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080287529-A1 | CRYSTAL STRUCTURES OF SGLT2 INHIBITORS AND PROCESSES FOR PREPARING SAME | SLC5A2, SLC5A1, SLC2A1 | SLC5A2 1/4885SLC5A1 2/4885KDM4E 2977/4885 |
| US-20140105839-A1 | FAMILY OF ARYL, HETEROARYL, O-ARYL AND O-HETEROARYL CARBASUGARS | SLC5A2, SLC5A1, SLC2A2 | SLC5A2 1/4885SLC5A1 2/4885KDM4E 3461/4885 |
| US-20060063722-A1 | C-aryl glucoside SGLT2 inhibitors and method | SLC5A2, SLC5A1, GCG | SLC5A2 1/4885SLC5A1 2/4885KDM4E 2440/4885 |
| US-20080132563-A1 | 1-Thio-D-Glucitol Derivatives | SLC5A1, SLC5A2, SLC5A11 | SLC5A2 2/4885SLC5A1 1/4885KDM4E 2838/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.